Compare BLIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | SKYE |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.4M |
| IPO Year | 2018 | 2013 |
| Metric | BLIN | SKYE |
|---|---|---|
| Price | $0.71 | $1.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $68.00 |
| AVG Volume (30 Days) | ★ 59.8K | 26.4K |
| Earning Date | 08-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $20.26 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $0.26 |
| 52 Week High | $1.42 | $13.12 |
| Indicator | BLIN | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 41.50 |
| Support Level | $0.69 | $1.52 |
| Resistance Level | $1.05 | $2.28 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 18.30 | 18.52 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.